Dihomo-gamma-linolenic acid in patients with atherosclerosis: effects on platelet aggregation, plasma lipids and low-density lipoprotein-induced inhibition of prostacyclin generation.
Dihomo-gamma-linolenic acid ( DHLA ), a precursor of monoenoic anti-aggregatory prostaglandins (PGE1, PGD2), was administered for 4 weeks in a daily dose of 1.0 g into 33 patients with atherosclerosis on a basis of a double-blind trial. Comparison of treatment and placebo groups revealed elevation of DHLA in red cell lipids in DHLA -treated subjects. No differences, however, between the two groups could be observed in platelet aggregability, thromboxane A2 generation by platelets, serum cholesterol, PGE1 and PGE2 levels, and in inhibitory activity of low-density lipoproteins against prostacyclin synthetizing system in arteries. The dietary supplementation used did not lead to distinct antithrombotic effects.
D015126:8,11,14-Eicosatrienoic Acid / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy*; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D015232:Dinoprostone; D011464:Epoprostenol / Q000097:blood*; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D011458:Prostaglandins E / Q000097:blood; D013928:Thromboxane A2 / Q000097:blood
D001786:Blood Glucose; D005231:Fatty Acids, Unsaturated; D008055:Lipids; D008077:Lipoproteins, LDL; D011458:Prostaglandins E; D013928:Thromboxane A2; D002784:Cholesterol; D011464:Epoprostenol; D015126:8,11,14-Eicosatrienoic Acid; D015232:Dinoprostone